Precision screening, analytical method establishment, and translational pharmacognosy services deployed across global pharmaceutical, nutraceutical, and cosmetic value chains.
In modern biopharmaceutical and nutraceutical engineering, "Plant Position" is no longer just a geographical location—it represents a rigorous matrix spanning botanical organomics, chronobiological harvest timing, geo-authentic chemotype zoning, and commercial continuous-extraction infrastructure.
The international botanical medicine and plant-derived active ingredient market is witnessing a structural transformation. Global regulatory authorities—including the U.S. FDA (under the Botanical Drug Guidance for Industry), the European Medicines Agency (HMPC/EMA), and China’s NMPA—are increasingly rejecting generic herbal extracts that lack batch-to-batch chemical fingerprint uniformity and metabolic provenance.
As an OEM/CDMO plant position manufacturer and supplier, MedGence solves the core industrial bottleneck: natural phytochemical fluctuation. Secondary metabolites such as flavonoids, triterpenoid saponins, phenolics, and alkaloids fluctuate violently based on plant tissue positioning (apical buds vs. taproots vs. cortical tissue), altitudinal exposure, diurnal solar radiation, and post-harvest drying thermodynamics. By instituting multi-spectral chromatographic profiling and geo-authenticated cultivation alignment, we guarantee targeted molecular yields, zero synthetic adulteration, and cGMP commercial scalability.
Global geopolitical turbulence and climate volatility have disrupted wild-harvested and single-region agricultural botanicals. MedGence maintains dual-engine risk mitigation:
MedGence (Yineng Pharma) is an authoritative contract research, development, and manufacturing organization based in Changsha, China, dedicated to natural medicine and plant-derived active ingredients across the complete pharmaceutical lifecycle.
We support multinational pharmaceutical, nutraceutical, dietary supplement, and cosmeceutical companies across the full value chain — from raw-material botanical screening and analytical fingerprinting to toxicity, preclinical animal testing, Phase I–IV clinical trials, and finished cGMP commercial dosage manufacturing.
Over 14+ years, our 300+ research scientists and technicians have delivered rigorous R&D programs for more than 100 leading pharmaceutical manufacturers and top-tier clinical hospitals, successfully modernized 83 classic Traditional Chinese Medicine (TCM) formulas into verifiable molecular products, engineered 22 innovative natural medicines, obtained 56 hospital preparation registrations, and codified official quality monographs and extraction processes for nearly 400 single-herb medicines.
“Natural medicine earns global trust only when every claim is backed by reproducible chemistry, validated methods and controlled studies. We combine classical TCM formulation experience with modern analytical and pharmacological tools, so each ingredient we deliver can be traced, quantified and defended in front of regulators and consumers.”— MedGence Scientific Leadership Team
Under our entrusted research and manufacturing model, your formulas, proprietary strains, solvent ratios, and process parameters remain strictly non-disclosed under stringent multi-jurisdiction NDAs.
Protected IP OwnershipOur proprietary chemotype database spans hundreds of thousands of research batches across natural raw botanicals, wild-harvested herbs, and hospital preparations, accelerating go/no-go decisions.
De-Risked Discovery MatrixConsult directly with our doctoral scientists on target indication modeling, organ-specific active yields, toxicity clearance paths, and compliant dosage execution.
Email Scientist Direct →Our proprietary Botanical Position Framework integrates Spatial Organomics, Chronobiological Seasonality, and Terroir-Driven Geo-Authentication to maximize therapeutic index while driving down commercial unit cost.
Active compounds do not distribute evenly throughout a plant. In Ginseng (Panax ginseng), for instance, ginsenosides Rb1, Rg1, and Re concentrate differentially between the rhizome root-hair, main root cortex, and aerial foliage. Sourcing the wrong anatomical plant position leads to 400% cost overruns during concentration. We systematically assay leaves, barks, seeds, flowers, roots, and rhizomes to isolate the apex source tissue.
Secondary metabolite biosynthesis peaks within narrow temporal windows dictated by photoperiod and temperature fluctuations. Harvesting Ginkgo biloba foliage during autumn senescence yields vastly altered flavonol-to-terpene lactone profiles compared to mid-summer harvest. MedGence conducts longitudinal seasonal potency evaluations across spring, summer, autumn, and dormant phases to pinpoint peak bioactivity.
The classic Chinese concept of "Daodi" (authentic geo-source) is verified through modern inductively coupled plasma mass spectrometry (ICP-MS) and genetic barcoding. Soil mineral content, UV exposure, and rhizosphere microbiomes trigger distinct enzymatic cascades. We benchmark botanical lots across varied origins (Sichuan vs. Yunnan vs. Changbai Mountains) to establish stable raw-material procurement pipelines.
| Botanical Target | Optimal Plant Position (Organ) | Optimal Harvest Window | Standardized Active Yield | Analytical Verification Method |
|---|---|---|---|---|
| Panax notoginseng | Rhizoma / Fibrous Rootlet | Pre-flowering Autumn (Oct) | Notoginsenoside R1 + Rg1 + Rb1 ≥ 11.5% | HPLC-DAD / Fingerprint Standard |
| Epimedium brevicornu | Aerial Folium (Mid-stem Leaves) | Late Summer Solar Peak (Aug) | Icariin ≥ 20.0% – 98.0% Purified | RP-HPLC / LC-MS Verification |
| Salvia miltiorrhiza | Root Cortex (Outer Bark Zone) | Dormant Early Winter (Nov-Dec) | Tanshinone IIA ≥ 2.5%, Salvianolic Acid B ≥ 8.0% | Ultra-Performance LC (UPLC-UV) |
| Astragalus membranaceus | Main Taproot (> 3 Years) | Late Autumn Post-Foliage Fall | Astragaloside IV ≥ 0.5% – 10.0%, Polysaccharides ≥ 50% | HPLC-ELSD / Spectrophotometry |
From de novo target screening and pharmacognosy assay design to industrial pilot engineering and full regulatory registration dossiers, our modular services guarantee scientific continuity.
Plants contain alkaloids, polysaccharides, saponins, and phenolics. Using our accumulated phytochemical database and high-throughput cellular screening platforms, we identify which substances deliver your target pharmacological effect—and which plant positions contain them at the highest density—balancing commercial cost efficiency with ecological sustainability.
Explore Discovery DataThe same botanical species varies widely in active-ingredient concentration depending on soil composition, microclimate, harvest calendar, and the anatomical plant part used. We quantify these variations through rigorous chromatography, enabling you to lock in the optimal origin, harvest window, and plant part for a high-yield sourcing protocol.
Explore Sourcing AssaysValidated testing protocols are the foundation of regulatory filings and market confidence. We establish identification and quantitative assays using HPTLC, HPLC-DAD, GC-MS, and chromatographic fingerprinting, providing your quality control team with bulletproof methodologies to verify identity, potency, and batch reproducibility.
Explore Analytical QCOnce a target molecule is confirmed, production economics decide global competitiveness. We optimize raw-material comminution, countercurrent extraction, macroporous resin adsorption, ultrafiltration, and vacuum freeze-drying parameters—ensuring high yield, high purity (>98%), and seamless commercial scale-up.
Explore Process StudiesConverting sensitive botanical extracts into shelf-stable commercial formats presents hurdles like hygroscopicity, poor solubility, and degradation. Our formulation scientists engineer microencapsulation, spray-drying excipient matrices, and liposomal carriers to preserve active bioavailability and deliver pleasant organoleptic properties.
Explore FormulationsSafety verification is the prerequisite for regulatory clearance. In our GLP-aligned testing facilities, we conduct median lethal dose (LD50), 28/90-day repeat oral toxicity, Ames bacterial reverse mutation, in vitro mammalian chromosomal aberration, and micronucleus assays to build unimpeachable safety dossiers.
Explore Tox PackagesPrimary cell lines and engineered bioassays demonstrate physiological mechanisms of action at fractions of the timeline and expenditure of whole-animal studies. In vitro data provides rapid go/no-go gating for metabolic control, anti-inflammatory cascades (NF-kB/COX-2), antioxidant efficacy, and neuroprotective pathways.
Explore In Vitro AssaysTargeted disease animal models (rodent metabolic syndrome, arthritis, cognitive impairment, and dermal wound repair) deliver decisive evidence of therapeutic efficacy and pharmacokinetic distribution, establishing sound scientific benchmarks for dietary supplements and botanical new drug candidates.
Explore In Vivo ModelsFor novel botanical actives and specialized formulas, we arrange randomized, double-blind, placebo-controlled clinical trials—ranging from small-cohort human efficacy and tolerability studies for nutraceutical claims to formal GCP Phase I–IV trials required for official New Drug Applications (NDA).
Explore Clinical ProtocolsDrawing on 14+ years of Traditional Chinese Medicine synergy principles and modern pharmacokinetics, we design multi-herb compatibility profiles that enhance bioavailability and mitigate off-target toxicity, providing fully substantiated turnkey formulas ready for intellectual property protection.
Explore Formulation IPDirectly managed by our senior technical team, our pilot and commercial partner extraction facilities translate research formulas into commercial reality. Actives are supplied in high-yield forms: purified crystalline powders, standardized concentrated liquids, dense pastes, and supercritical volatile oils.
Request Actives CatalogTurnkey cGMP production lines for commercial consumer dosage formats: oral liquids, hard-shell capsules, softgels, multi-layer tablets, effervescent granules, and functional drink powders—backed by strict batch release testing, full documentation, and unwavering NDA client protection.
Request Dosage SpecsStrategic equipment positioning inside modern cGMP botanical processing facilities is vital to prevent thermal degradation, cross-contamination, and volatile fraction loss.
Our industrial plant layout follows strict Class D and Class C cleanroom zonation. Raw botanical intake, pneumatic air classification, and cryogenic milling are physically isolated from aqueous-organic solvent extraction halls to prevent spore and particulate contamination.
MedGence is pioneering the integration of machine learning into industrial plant positioning. By feeding multi-batch HPLC spectra and spectroscopic NIR readings into deep neural networks, our systems predict:
• Predictive Phytochemical Degradation Modeling under varying temperature/humidity.
• Real-Time Extraction Endpoint Detection using in-line fiber-optic UV-Vis probes.
• Molecular Docking & Synergy Algorithms predicting multi-component herbal affinity to human drug targets.
Engage MedGence for individual specialized studies or our comprehensive contract research and manufacturing pipeline. Every milestone terminates with a defined, legally auditable deliverable.
Identify the most potent target bioactives and determine the precise plant origin, harvest season, and anatomical plant position exhibiting maximal active accumulation.
Develop and validate identification tests, quantitative assays via HPLC, HPTLC, and GC-MS, and chromatographic fingerprint profiles alongside raw material release specifications.
Establish critical process parameters (CPPs) across pretreatment, thermal extraction, column chromatography separation, concentration, and commercial dosage stability.
Execute GLP-standard in vitro bioassays, disease animal models, LD50 acute toxicity, subchronic toxicity, and mutagenic genotoxicity clearance packages.
Manage randomized small-group human trials for dietary supplement claim substantiation or GCP-compliant Phase I, II, III, and IV clinical trials supporting formal drug registration.
Pilot and commercial cGMP OEM/CDMO production batches under rigorous quality assurance, ensuring timely supply, cold-chain integrity, and absolute client IP confidentiality.
A tangible track record built over 14+ years alongside China’s leading listed pharmaceutical groups, top TCM research academies, and university hospitals.
Tailoring botanical active specifications and delivery formats to meet regional regulatory frameworks: DSHEA in North America, Traditional Herbal Medicinal Products Directive (THMPD) in Europe, and NMPA in East Asia.
High-density standardized botanical extracts, evidence-backed synergized formulas, and human clinical tolerability trials designed to substantiate high-visibility structure/function claims across demanding e-commerce and retail pharmacy distribution.
De-risked active-compound identification, isolation, chemical structural characterization, GLP preclinical safety profiles, and Phase I–IV clinical study execution built upon our documented track record of 22 innovative natural medicines developed.
Clean-label, skin-penetrating botanical actives validated through human keratinocyte assays, tyrosinase inhibition assays, and clinical skin patch testing, giving cosmetic brands substantiated clean-beauty claims with zero synthetic additives.
Supplied under strict nitrogen-flushed, moisture-barrier packaging tailored for industrial secondary processing:
Manufactured on cGMP certified automated packaging and filling lines:
Our natural medicine R&D and commercial contract manufacturing support China’s most prestigious state-owned and listed pharmaceutical groups, medical universities, and hospital preparation centers.
China Beijing Tongrentang Group
China Resources Sanjiu Medical & Pharmaceutical
Sunflower Pharmaceutical Group
Livzon Pharmaceutical Group
Dihon Pharmaceutical Group
Golden Throat Holdings Group
Yangtzi River Pharmaceutical Group
Beihai Gofar Chuanshan Biological
Humanwell Healthcare Group
SCIMYTH Pharmaceutical Group
Shandong Hanfang Pharmaceutical
Luoxin Pharmaceutical Group
Guangdong Zhongsheng Pharmaceutical
Hunan Brilliance & Abundance Scientific Chinese Herbal Medicine
Apeloa Pharmaceutical
Hunan Heng Chang Pharmaceutical Group
Baotou Traditional Chinese Medicine
Kamp Medicine
Guangxi Santo Pharmaceutical
Hunan Kangshou Pharmaceutical
Jiangxi Juwang Pharmaceutical Industry
Beijing Tcmages Pharmaceutical
Guizhou Ruihe Pharmaceutical
Anhui CR Jinchan Pharmaceutical
Kangmei Pharmaceutical
Hunan Tianjicaotang Pharmaceutical
Jiangxi Kingstone Unite Pharmaceutical
Shuguang Hospital, Shanghai University of TCM
Hunan Province Directly Affiliated TCM Hospital
First Hospital of Hunan University of Chinese Medicine
Second Xiangya Hospital of Central South University
Second Hospital of Hunan University of Chinese Medicine
Orthopedics of TCM Zhuzhou CityExhaustive answers addressing compliance, analytical methods, IP ring-fencing, and contract development scaling.
Direct access to our contract research programs. Inquire today for technical scopes, turnaround times, and study validation parameters.
Get our complete technical catalog detailing study scopes, analytical protocols, batch COAs, and available commercial dosage formats. Or submit your target compound brief directly to our senior scientific review board.
MedGence Technical Co., Ltd. (Yineng Pharma)
Room 101, Building 1, No. 31 Qianfutang Road, Dongfanghong Subdistrict, Yuelu District, Changsha City, Hunan Province, China
